

1 **High Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome Among US**

2 **Adults From 1999-2020 – An analysis of the NHANES survey**

3

4 Zhejia Tian<sup>1</sup>, Samira Soltani MD<sup>3</sup>, Johann Bauersachs MD<sup>3</sup>, Kai Schmidt-Ott MD<sup>1</sup>, \*Anette Melk  
5 MD, PhD<sup>2</sup>, \*Bernhard MW Schmidt MD, SM<sup>1</sup>

6

7 <sup>1</sup>Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany

8 <sup>2</sup>Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School,  
9 Hannover, Germany

10 <sup>3</sup>Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany

11

12 \*These authors contributed equally.

13

14

15

16

17

18

19 Corresponding author:

20 Bernhard M.W. Schmidt, MD, SM

21 Department of Nephrology and Hypertension, Hannover Medical School, Germany

22 Carl-Neuberg-Straße 1

23 30625 Hannover

24 Germany

25 Tel. +49511-532-2329

26 [schmidt.bernhard@mh-hannover.de](mailto:schmidt.bernhard@mh-hannover.de)

27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 **Background**

3 The cardiovascular-kidney-metabolic (CKM) syndrome is a newly defined chronic health  
4 condition from American Heart Association. We assessed the prevalence of CKM syndrome  
5 stages 0-2, which have not yet progressed to cardiovascular disease (stage 3-4) with trends  
6 analysis over the past two decades.

7 **Methods**

8 We used cross-sectional data provided by National Health and Nutrition Examination Survey.  
9 including non-pregnant participants aged 18 or older between 1999 and 2020. Weighted  
10 prevalence was analyzed over the course of the past 20 years and by population subgroup  
11 (including age, sex, and race/ethnicity).

12 **Results**

13 A total of 32848 US adults were included in our study (weighted mean age, 47.3 years;  
14 women, 51.3%). 7.9% of US adults were at stage 0 without any CKM risk factors, with 64% of  
15 this subgroup being female. 18.3% of US adults were classified as stage 1 with issues related  
16 to excess or dysfunctional adiposity without other metabolic risk factors or chronic kidney  
17 disease (CKD). More than half of the US adults (56.5%) exhibited either metabolic risk  
18 factors, CKD, or both (stage 2). Between 1999 and 2020, the CKM features increased with  
19 decreasing prevalence of stage 0 (P for trends =0.0018), not only in females but also in  
20 males.

21 **Conclusions**

1 Our findings illustrate an exceptionally high and increasing prevalence of CKM syndrome  
2 among US adults. This emphasizes the importance of comprehensive preventive strategies  
3 targeting the life style of large parts of the population. Moreover, further risk assessment  
4 should be implemented into stage 2 cohort to define patients with exceptional  
5 cardiovascular risk.

6 **Keywords:** cardiovascular-kidney-metabolic syndrome, cardiovascular disease, chronic  
7 kidney disease, metabolic risks, epidemiology

8

## 1 **Clinical Perspective**

### 2 **What is new?**

- 3 ● CKM syndrome is a common chronic health condition in the general population. However,  
4 the prevalence of different CKM stages using real-world data has not been reported within  
5 the general population or its subgroups.
- 6 ● The prevalence of CKM syndrome was increasing over the past two decades. The majority  
7 of US adults were classified as stage 2.
- 8 ● A specific population remained undefined according to the current detailed definition of  
9 each CKM syndrome stage.

### 10 **What are the clinical implications?**

- 11 ● The high and increasing prevalence of CKM syndrome necessitates more precise  
12 preventive strategies, tailored to different target groups with consideration of age-, sex-,  
13 and gender-disparities.
- 14 ● Given that approximately half of the study population fell into stage 2 with a wide  
15 spectrum of risk factors, it is imperative to identify patients with exceptionally high risk  
16 through additional risk assessments. This approach would facilitate the implementation  
17 of intensified treatment measures aimed at preventing the progression to cardiovascular  
18 disease (CKM syndrome stages 3-4).

## 1 **Abbreviations and Acronyms**

BMI	Body mass index
CKD	Chronic kidney disease
CKM syndrome	Cardiovascular-kidney-metabolic syndrome
CVD	Cardiovascular disease
eGFR	Estimated glomerular filtration rate
MetS	Metabolic syndrome
NHANES	National Health and Nutrition Examination Survey
UACR	Urinary albumin to creatinine ratio

2

3

## 1 **Introduction**

2 The cardiovascular-kidney-metabolic (CKM) syndrome is a recently defined chronic health  
3 condition characterized as a systemic disorder that signifies intricate interactions among  
4 metabolic risk factors, chronic kidney disease (CKD), and the cardiovascular system. It  
5 transcends the simple sum of its components, leading to multiorgan dysfunction and  
6 increased adverse cardiovascular outcomes <sup>1,2</sup>. Four stages of CKM syndrome were outlined:  
7 stage 0, characterized by the absence of CKM risk factors; stage 1, marked by excess or  
8 dysfunctional adiposity; stage 2, involving metabolic risk factors and/or CKD; and stages 3-4,  
9 defined by subclinical (stage 3) or clinical (stage 4) CVD alongside CKM risk factors <sup>1,2</sup>. Based  
10 on the latest heart disease and stroke statistics update, it is indicated that one in three adults  
11 in the United States has three or more risk factors contributing to the deterioration of CKM  
12 health. The overall prevalence of cardiovascular disease, including hypertension, coronary  
13 heart disease, heart failure, and stroke, stands at 48.6% among adults aged 20 and older <sup>3</sup>.  
14 This highlights a substantial burden of CKM syndrome within the general population,  
15 underscoring the imperative for extensive healthcare initiatives.

16 Despite the significant challenges in managing poor CKM health, a comprehensive  
17 classification and risk assessment of CKM syndrome also provides us with opportunities to  
18 detect early stages for preventive measures and implement effective interventions, thereby  
19 decelerating progression. This is particularly important given the recent expansion of  
20 therapeutic innovations, such sodium-glucose co-transporter 2 inhibitors and glucagon-like  
21 peptide 1 receptor agonists <sup>4-8</sup>. Additionally, optimizing CVD health necessitates the

1 integration of social determinants, behavioral interventions, early-life prevention,  
2 multidisciplinary care, and ensuring affordable access to pharmacotherapy<sup>9-11</sup>.  
3 Extensive research and analyses were conducted to examine the impact of metabolic risks,  
4 CKD, and cardiovascular disease, along with their intersections<sup>3,12-16</sup>. Despite these efforts,  
5 the prevalence of CKM syndrome, categorized by specific stages, remains undefined at this  
6 time. Using data from the National Health and Nutrition Examination Survey (NHANES), this  
7 analysis was intended to delineate the prevalence and distribution of CKM syndrome with a  
8 specific focus on stage 0-2 among US adults, aiming to identify subpopulations at risk for  
9 progression to stage 3-4 and to explore the trends of the prevalence over the last 20 years.  
10

## 1 **Methods**

### 2 **Data Source and Study Population**

3 The NHANES has been conducted continuously in 2-year cycles since 1999. It employs a  
4 cross-sectional survey design to assess the health and nutritional status of adults and  
5 children in the United States, utilizing a complex, multistage, probability sampling design.  
6 The survey is representative for the non-institutionalized, civil population of the United  
7 States. Written informed consent was obtained from all survey participants, and the study  
8 procedures receive approval from the National Center for Health Statistics Research Ethics  
9 Review Board. The Hannover Medical School Institutional Review Board exempted the  
10 present study because it did not constitute human subject research. We followed the  
11 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting  
12 guideline throughout our study <sup>17</sup>.

13 We included non-pregnant participants aged 18 or older from 10 NHANES cycles starting  
14 with the 1999-2000 cycle until 2017-March 2020 cycle in our analysis. All participants should  
15 possess sufficient information to determine cardiovascular disease based on self-report. All  
16 survey cycles were applied to evaluate the trends in the prevalence of CKM Stage 0-2 and  
17 were combined to analyze the overall prevalence.

### 18 **Data Collection**

19 Demographic information was collected through household questionnaires. Race and  
20 ethnicity were not consistently reported in NHANES: non-Hispanic Asian participants were  
21 not classified and oversampled until 2011. In our analysis, we categorized self-reported



1 Mexican American and other Hispanic individuals as Hispanic race and ethnicity.

2 Data of Body mass index, waist circumference and blood pressure were available among  
3 participants who underwent clinical examination. Standardized blood pressure  
4 measurements were performed: three consecutive measurements were taken at one-minute  
5 intervals, and the average of the last two measurements was applied to our analysis <sup>18</sup>.

6 Hypertension was defined by either elevated blood pressure according to 2017 AHA  
7 guideline <sup>19</sup> or the use of antihypertensive medication.

8 Chronic kidney disease (CKD) is classified by estimated glomerular filtration rate (eGFR) and  
9 albuminuria according to KDIGO 2012 Guidelines as outlined in S1 Table <sup>20</sup>. Urinary albumin  
10 to creatinine ratio (UACR) was extracted, if available, directly from medical examination data  
11 or was calculated from urinary albumin and urinary creatinine. We calculated eGFR using the  
12 2021 race- and ethnicity-free Chronic Kidney Disease Epidemiology Collaboration creatinine  
13 equation <sup>21</sup>.

14 For lipid profiles, we considered medication use based on self-report and laboratory  
15 examination of serum triglyceride, HDL-cholesterol and LDL-cholesterol. 2018 AHA guideline  
16 recommendations were applied to define the normal lipid condition <sup>22</sup>.

17 We evaluated diabetes conditions using self-reported information on glucose-lowering  
18 therapy, medical examination of glycated hemoglobin and fasting serum glucose. The  
19 presence of diabetes or prediabetes was defined based on diagnostic tests outlined in the  
20 2023 ADA guidelines <sup>23</sup>

## 21 **Statistical Analysis**

1 We first applied a selection strategy consistent with the definitions of CKM syndrome stage  
2 0-2<sup>1</sup> (S2 Table) to identify individuals meeting the criteria for stage 0-2 in each survey cycle  
3 and in overall combined cycles. We then accounted for the complex survey design factors for  
4 NHANES, such as sample weights, clustering, and stratification, as specified in the National  
5 Center for Health Statistic analytic guideline<sup>24</sup>. In all analysis, morning fasting subsample  
6 weights and Taylor series linearization method were applied to estimate prevalence and  
7 standard errors representative of the civilian, noninstitutionalized US population <sup>25,26</sup>. Each  
8 prevalence estimate was reported with corresponding 95% confidence interval (95% CI). For  
9 trends analysis across cycles, survey-weighted logistic regression was employed, with survey  
10 cycle as a continuous variable. 2-sided  $P < 0.05$  was considered statistically significant.  
11 Sensitivity analyses were conducted to examine the influence of non-response on our main  
12 analysis. We first adjusted sample weights with the adjustment cell method <sup>27</sup>. Moreover,  
13 multivariate multiple imputation by chained equations with 5 imputations was performed to  
14 address missing data<sup>28</sup>. All Analyses were conducted using R version 4.3.2.  
15

## 1 **Results**

### 2 **Study Population Characteristics**

3 Over these 10 survey cycles, 32848 participants aged 18 or older were included in our final  
4 study, representing 215480397 noninstitutionalized US inhabitants (Table 1). Of all  
5 participants, mean (SE) age was 47.3 (0.2), 51.3% were female and 48.7% were male.  
6 Participants between 18 and 24 years old constituted 9.2% of the total, with 37.1% aged  
7 between 25 and 44, 35.6% between 45 and 64. 18.1% were aged 65 or older. More than 60%  
8 were Non-Hispanic White. Of the total, 13.8% identified as Hispanic, 11.1% as Non-Hispanic  
9 Black, 2.6% as Non-Hispanic Asian, and 4.5% reported as other race or ethnicity.

10

### 11 **Overall Prevalence of CKM Syndrome Stages**

12 The prevalence of different CKM syndrome stages with different population characteristics is  
13 summarized in Table 1. A total of 82.3% noninstitutionalized US adults were our target  
14 population, who would benefit from preventive cardiovascular assessments. Only 7.9% of  
15 the US adults showed no CKM risk factors and fulfilled the criteria for CKM syndrome stage 0,  
16 with the majority being female, comprising 64% of this subgroup. A higher percentage of  
17 younger participants were categorized in this group, with 74.9% being under the age of 45  
18 years. 18.3% encountered issues related to excess or dysfunctional adiposity (stage 1) with a  
19 similar distribution between sexes. The proportion of the middle-aged population (45-64  
20 years old) increased to 30.6% compared to this age group in stage 0. Over half of the US  
21 adults (56.5%) exhibited either metabolic risk factors, CKD, or a combination of both and met  
22 the criteria for inclusion in stage 2. 49.3% of the participants stage 2 were female and 50.7%

1 were male. Older individuals were more prevalent in Stage 2: among the participants at stage  
2 2 41.1% were between the ages of 45-64 and 20.4% aged 65 or older.

3

#### 4 **Prevalence of CKM Syndrome Stages stratified by Sex, Age, and Race/Ethnicity**

5 In comparison to females, males tended to experience CKM risk factors more frequently,  
6 with 19.2% of the overall male participants vs. 17.4% of the overall female participants  
7 exhibiting stage 1 CKM syndrome and 58.9% vs. 54.4% showing stage 2 (Figure 1A).  
8 Participants of advanced age were associated with higher CKM stage in US population  
9 without CVD. 81.1% of participants between 44 and 64 years and 69.6% of aged 65 years or  
10 older were attributed to either stage 1 or stage 2. While younger participants demonstrated  
11 a lower CKM risk, as illustrated in Figure 1B, a relatively high proportion of CKM stage 2 were  
12 still observed among those aged 18 to 24 years (35.4%) and those aged 25 to 44 years  
13 (49.9%). Relative to males, females at a younger age were associated with a lower CKM risk  
14 (age group 18-44 in stage 0-1: 4% of US adults vs. 2.4%), while females with increasing age  
15 showed an increasing proportion of CKM stage 2 with 18.8% of US adults aged 45 or older  
16 compared to 16% for males (Figure 1C, S3 Table). Across all race and ethnicity groups, the  
17 proportions of CKM Stage 0-2 were comparable (Figure 1D).

18

#### 19 **Prevalence of Metabolic Risk Factors and CKD in CKM Stage 2**

20 Among all US adults with CKM stage 2, hypertension ranked as the most prevalent  
21 component (70.6%), followed by hypertriglyceridemia at 52.4% and metabolic syndrome

1 (MetS) at 42.6%. The prevalence of CKD (16.4%) and diabetes (16.4%) were lower (Figure 2).  
2 S1-5 Figure illustrate the sex- and age-stratified prevalence of different components in CKM  
3 Stage 2. Overall, CKD was more common among females than males across all age groups,  
4 particularly in the age group of 65 years or older (23.6% of the participants at stage 2 with  
5 CKD vs. 13.9%,  $P < 0.001$ ). At a younger age, females had a lower prevalence of hypertension  
6 compared to males (age group 18-24: 1.0% of the participants at stage 2 with hypertension  
7 vs. 2.4%,  $P < 0.001$ ; age group 25-44: 10.2% vs. 16.4%,  $P < 0.001$ ). Hypertension was however  
8 more prevalent in women aged 65 or older (15.2% vs. 9.9%,  $P < 0.001$ ). The prevalence  
9 distribution of hypertriglyceridemia, when stratified by sex and age, was similar to that of  
10 hypertension. Females aged 65 or older carried a higher burden of MetS (11.3% of the  
11 participants at stage 2 with MetS vs. 6.6%,  $P < 0.001$ ). The prevalence of diabetes was similar  
12 among females and males in all age groups.

13

#### 14 **Trends in Prevalence of CKM Stages**

15 The comprehensive trend analysis for overall and sex-/age-stratified prevalence of CKM  
16 stages is summarized in Table 2. Overall, the proportion of US adult population in CKM stage  
17 0 decreased from 7.9% in the 1999 to 2000 cycle to 6.8% in the 2017 to 2020 cycle ( $P$  for  
18 trend = 0.0018) (Figure 3). This declining trend was evident not only in females, with a  
19 reduction from 5.2% to 4.2% ( $P$  for trend= 0.0039), but also in males, with a slight decrease  
20 from 2.7% to 2.6% ( $P$  for trend = 0.031) (Figure 4). Additionally, there was a significant  
21 decrease in CKM stage 0 within the population aged 25 to 44 years (from 5.3% to 3.6%,  $P$  for

1 trend < 0.001) (Figure 5A). For CKM stage 2, participants aged between 25 to 44 years  
2 demonstrated a substantial reduction from 23.2% to 16.8% ( $P$  for trend = 0.018),  
3 accompanied by a noteworthy increase in the proportion of participants aged 65 years or  
4 older (from 10.3% to 13.2%,  $P$  for trend < 0.001) (Figure 5C). The overall and sex-/age-  
5 stratified trends in CKM stage 1 remained relatively constant (Figure 3, Figure 4B and Figure  
6 5B).

## 8 **Population with undefined CKM Stages**

9 During the selection process for each CKM stage, we identified specific subgroups that  
10 remained undefined. This included participants, for example, only with abnormal HDL-  
11 cholesterol or LDL-cholesterol. These participants fulfill neither the definition of stage 0  
12 (normal lipid profile) nor of stage 1. As depicted in Figure 6, participants with undefined  
13 stage comprised 3.3% of the overall US adult population, with 62.3% (4.0% of the overall  
14 female adult population) being female and 37.7% (2.6% of the overall male adult population)  
15 being male. After incorporating this proportion of undefined subgroup into CKM stages 0-2,  
16 the sex-stratified prevalence of CKM stages 0-2 became comparable.

## 18 **Sensitivity Analysis**

19 After reweighting for nonresponse, we observed no significant deviation from our main  
20 analysis (S4 Table). The aggregated outcome from 5 imputations, following the imputation of  
21 missing data, aligned consistently with the main analysis. (S5 Table).

## Discussion

Our analysis of this nationally representative survey of US adults reveals a high prevalence of CKM syndrome in the general population. Signs of CKM syndrome were absent in only less than 10% of US adults. Even among younger adults, we observed a higher burden of CKM syndrome: 1 in 4 US adults aged between 18-24 years had stage 1, and 1 in 3 exhibited stage 2. Women aged 65 or older were at the highest risk for CKM syndrome stage 2. From 1999-2000 through 2017-2020, the prevalence of CKM stage 0 decrease from 7.9% to 6.8%. Furthermore, the prevalence of various metabolic risk factors and CKD in CKM syndrome stage 2 varied across sex and age.

A prior study, which examined cardiovascular disease, CKD, and diabetes among US adults, using also the NHANES survey, showed a high and increasing prevalence of cardiac, renal and metabolic multimorbidity<sup>13</sup>. Our analysis further confirms the high burden of CKM syndrome after applying defined criteria for each stage. However, the focus is on the population at stages 0-2, who have not yet developed subclinical or clinical CVD, to identify the demographic subsets who would profit from interdisciplinary comprehensive preventive strategies for achieving a reduction in cardiovascular and mortality risks.

CKM syndrome is an evolving condition that begins already in childhood<sup>29,30</sup>. Current evidence demonstrates that trends in CKM syndrome have been increasing in young adulthood despite the general improvement of health care<sup>1,31-33</sup>. In this analysis, we observed a high prevalence of poor CKM health in younger US adult population, with CKM syndrome absent in only 20% of adults aged between 18-24 years and 12.4% adults aged between 25-44 years. Over the past two decades, younger adults have exhibited a significant decreasing trend in the prevalence of stage 0, demonstrating a shift towards less favorable CKM health. These observations imply an escalating burden of CKM syndrome in the future

as these younger demographic ages, unless the adverse trends in the prevalence of CKM risk factors can be reversed. To reinforce initiatives promoting the CKM health of young adults, the public health policymakers should comprehend the unique interplay of biological, interpersonal, socioeconomic disparities and behavioral features that characterize this life stage. For instance, young adults could be more motivated to access their health records using mobile/wearable devices. Healthcare providers could, therefore, collaborate with patients to provide personalized medical advice by integrating these digital data <sup>34,35</sup>. In addition, more CKM health trials should be conducted with a focus on including participants under 45 years old, as young adults have been underrepresented in behavioral and pharmacologic prevention/ intervention trials so far <sup>36-39</sup>.

For the effective management of CKM syndrome, it's essential to also consider sex and age disparities in order to prevent a progression into stage 3-4. In CKM syndrome stage 2, for example, as women reached an older age ( $\geq 65$  years), they showed a significant higher prevalence across almost all metabolic risk factors and CKD compared to men in the same age group. Notably, this higher prevalence persisted in CKD, regardless of age. According to US Renal Data system 2023 annual Report, women have experienced more often CKD than men since 2005-2008 <sup>12</sup>. Several studies demonstrated a significant deterioration in lipid profiles and an increasing prevalence of MetS with menopause, beyond the effects of chronological aging, leading to a remarkable CKM progression and thus an increase of CVD absolute risk after menopause <sup>40-43</sup>. We also observed that men at younger age had significant higher prevalence of hypertension, MetS and hypertriglyceridemia. To address this unmet need referred to sex- and age-disparities, additional efforts should be directed towards research fields, clinical practice, and guideline development.

Despite the detailed definition of each CKM syndrome stage, a specific population remained



undefined, who had one or two abnormal lipid parameters. For an optimal risk assessment, accurately categorizing this subgroup population is essential. Besides, current evidence demonstrated a U-shaped correlation between HDL-cholesterol and cardiovascular risk<sup>44–47</sup>. For classification of CKM syndrome stages, very high HDL-cholesterol level should be considered as a risk factor. Furthermore, CKM syndrome stage 2 encompasses a broad spectrum of chronic conditions and includes more than half of the US adult population. Following the implementation of an enhanced screening system, a certain segment population from stage 2 may be categorized into stage 3. Concurrently, a refined risk assessment tool should be integrated with the CKM staging system to identify individuals at higher risk of CVD, with the goal of ensuring individualized healthcare. The new PREVENT model incorporates not only the traditional CVD risk factors but also kidney function along with other predictors such as UACR, HbA1c, and social determinants, as additional add-on model approach<sup>9</sup>. We propose defining a new CKM syndrome stage for individuals in stage 2 but at higher risk of CVD after applying PREVENT risk assessment, positioned between stage 2 and stage 3.

This study has several limitations. First, it comprises only the noninstitutionalized, civilian population, thus does not capture the individuals in nursing homes or the military. Second, non-Hispanic Asian participants were not classified and oversampled until 2011. This subgroup population might be under-represented in our study. Third, we didn't distinguish between diabetes mellitus types. This decision was based on our opinion that type 1 diabetes should also be included in CKM syndrome due to its association with CKD progression and higher cardiovascular risk. Finally, nonresponse might substantially influence our conclusion. However, sensitivity analyses, one after reweighting for nonresponse and another after imputing missing data, demonstrated comparable results, which confirmed our

main analysis.

## **Conclusion**

The definition of CKM syndrome is an important step in increasing awareness for the deleterious interplay of obesity, metabolic and renal factors in causing cardiovascular sequelae. Our study illustrates an exceptionally high burden of CKM syndrome among US adults, mirroring trends observed in all Western countries. Given the high prevalence of stage 2 of CKM syndrome, additional risk assessment is mandatory to tailor preventive measures on the population level to efficiently reduce cardiovascular morbidity and mortality.

## **Acknowledgements**

No other individuals contributed to this study substantively.

## **Sources of Funding**

There is no funding source in this study.

## **Disclosures**

SS received honoraria from AstraZeneca for lectures and consulting and from KelCon for lectures, not related to this article.

JB received honoraria for lectures/consulting from Novartis, Vifor, Bayer, Pfizer, Boehringer Ingelheim, AstraZeneca, Cardior, CVRx, BMS, Amgen, Corvia, Norgine, Edwards, Roche not related to this article; and research support for the department from Zoll, CVRx, Abiomed, Norgine, Roche, not related to this article.

KSO received lecture fees and honoraria from Boehringer Ingelheim, Astrazeneca, Bayer, Vifor, Alexion, Novartis, BioPorto Diagnostics and Abionyx, not related to this article.

BMWS received lecture fees and honoraria from ADVITOS, Amgen, Bayer Vital, Berlin Chemie-Menarini, CytoSorbents, Daichii Sankyo, Miltenyi, Pocard, not related to this article.

## References

1. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, Coresh J, Mathew RO, Baker-Smith CM, Carnethon MR, Despres J-P, Ho JE, Joseph JJ, Kernan WN, Khera A, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2023;148(20):1606–1635.
2. Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, Coresh J, Baker-Smith CM, Carnethon MR, Després JP, Ho JE, Joseph JJ, Kernan WN, Khera A, Kosiborod MN, et al. A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association. *Circulation*. 2023;148(20):1636–1664.
3. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, Commodore-Mensah Y, Elkind MSV, Evenson KR, Eze-Nliam C, Fugar S, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*. 2023;147(8):E93–E621.
4. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. *The New England journal of medicine*. 2020;383(15):1413–1424.
5. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. *The New England journal of medicine*. 2019;380(4):347–357.
6. Heerspink HJL, Stefánsson B V., Correa-Rotter R, Chertow GM, Greene T, Hou F-F, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde A-M, Wheeler DC. Dapagliflozin in Patients with Chronic Kidney Disease. *New England Journal of Medicine*. 2020;383(15):1436–1446.
7. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. *The New England journal of medicine*. 2016;375(19):1834–1844.
8. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. *The New England journal of medicine*. 2023;389(24):2221–2232.
9. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, Palaniappan LP, Sperling LS, Virani SS, Ho JE, Neeland IJ, Tuttle KR, Singh RR, Elkind MSV, Lloyd-Jones DM. Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. *Circulation*. 2023;148(24):1982–2004.
10. Joseph JJ, Deedwania P, Acharya T, Aguilar D, Bhatt DL, Chyun DA, Di Palo KE, Golden SH, Sperling LS. Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association. *Circulation*. 2022;145(9):722–759.
11. Ortiz A, Wanner C, Gansevoort RT, Cozzolino M, Fliser D, Gambaro G, Ong A, Rosenkranz AR, Rychlík I, Sarafidis P, Torra R, Tuglular S. Chronic kidney disease as cardiovascular risk factor in routine clinical practice: a position statement by the Council of

the European Renal Association. *European Journal of Preventive Cardiology*. 2022;29(17):2211–2215.

12. United States Renal Data System. 2023 Annual Data Report - CKD in the General Population. Accessed January 16, 2024. <https://usrds-adr.niddk.nih.gov/2023/chronic-kidney-disease/1-ckd-in-the-general-population>

13. Ostrominski JW, Arnold S V., Butler J, Fonarow GC, Hirsch JS, Palli SR, Donato BMK, Parrinello CM, O’Connell T, Collins EB, Woolley JJ, Kosiborod MN, Vaduganathan M. Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999–2020. *JAMA cardiology*. 2023;8(11):1050–1060.

14. Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, Long MW, Gortmaker SL. Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. *The New England journal of medicine*. 2019;381(25):2440–2450.

15. Chobufo MD, Gayam V, Soluny J, Rahman EU, Enoru S, Foryoung JB, Agbor VN, Dufresne A, Nfor T. Prevalence and control rates of hypertension in the USA: 2017–2018. *International Journal of Cardiology Hypertension*. 2020;6.

16. Centers for Disease Control and Prevention. National Diabetes Statistics Report 2021. Accessed January 16, 2024. website. <https://www.cdc.gov/diabetes/data/statistics-report/index.html>.

17. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet (London, England)*. 2007;370(9596):1453–1457.

18. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, Ramirez A, Schlaich M, Stergiou GS, Tomaszewski M, Wainford RD, Williams B, Schutte AE. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. *Hypertension (Dallas, Tex. : 1979)*. 2020;75(6):1334–1357.

19. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbigele B, Smith SC, Spencer CC, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Hypertension (Dallas, Tex. : 1979)*. 2018;71(6):1269–1324.

20. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Annals of internal medicine*. 2013;158(11):825–830.

21. Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, Crews DC, Doria A, Estrella MM, Froissart M, Grams ME, Greene T, Grubb A, Gudnason V, Gutiérrez OM, et al. New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race. *The New England journal of medicine*. 2021;385(19):1737.

22. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, et al. 2018

AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2019;73(24):3168–3209.

23. Elsayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, Collins BS, Hilliard ME, Isaacs D, Johnson EL, Kahan S, Khunti K, Kosiborod M, Leon J, Lyons SK, et al. 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes-2023. *Diabetes care*. 2023;46(Suppl 1):S19–S40.
24. National Center for Health Statistics. NHANES survey methods and analytic guidelines. US Centers for Disease Control and Prevention. Accessed April 1, 2022. Accessed January 5, 2024. <https://wwwn.cdc.gov/nchs/nhanes/analyticguidelines.aspx>
25. National Health and Nutrition Examination Survey: Analytic Guidelines, 2011-2014 and 2015-2016. Published December 14, 2018. Accessed January 5, 2024. <https://wwwn.cdc.gov/nchs/data/nhanes/analyticguidelines/11-16-analytic-guidelines.pdf>
26. Chen T-C, Clark J, Riddles MK, Mohadjer LK, Fakhouri THI. National Health and Nutrition Examination Survey, 2015–2018 : sample design and estimation procedures. 2020.
27. Chen Q, Gelman A, Tracy M, Norris FH, Galea S. Incorporating the sampling design in weighting adjustments for panel attrition. *Statistics in medicine*. 2015;34(28):3637.
28. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by chained equations in R. *Journal of Statistical Software*. 2011;45(3):1–67.
29. Larqué E, Labayen I, Flodmark CE, Lissau I, Czernin S, Moreno LA, Pietrobelli A, Widhalm K. From conception to infancy - early risk factors for childhood obesity. *Nature reviews. Endocrinology*. 2019;15(8):456–478.
30. von der Born J, Baberowski S, Memaran N, Grams L, Homeyer D, Borchert-Mörlins B, Sugianto RI, Paulsen M, Bauer E, Grabitz C, Schmidt BMW, Kerling A, Beerbaum P, Stiesch M, Tegtbur U, et al. Impact of Sex and Obesity on Echocardiographic Parameters in Children and Adolescents. *Pediatric cardiology*. 2022;43(7):1502–1516.
31. Cheng HL, Medlow S, Steinbeck K. The Health Consequences of Obesity in Young Adulthood. *Current obesity reports*. 2016;5(1):30–37.
32. Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. *Nature reviews. Cardiology*. 2018;15(4):230–240.
33. Zhou B, Lu Y, Hajifathalian K, Bentham J, Di Cesare M, Danaei G, Bixby H, Cowan MJ, Ali MK, Taddei C, Lo WC, Reis-Santos B, Stevens GA, Riley LM, Miranda JJ, et al. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet (London, England)*. 2016;387(10027):1513–1530.
34. Miyamoto SW, Henderson S, Young HM, Pande A, Han JJ. Tracking Health Data Is Not Enough: A Qualitative Exploration of the Role of Healthcare Partnerships and mHealth Technology to Promote Physical Activity and to Sustain Behavior Change. *JMIR mHealth and uHealth*. 2016;4(1).
35. Mahoney MR, Asch SM. Humanwide: A Comprehensive Data Base for Precision Health in Primary Care. *Annals of Family Medicine*. 2019;17(3):273.
36. Lanoye A, Grenga A, Leahey TM, LaRose JG. Motivation for weight loss and association with outcomes in a lifestyle intervention: comparing emerging adults to middle aged adults. *Obesity Science & Practice*. 2019;5(1):15.
37. Gokee-Larose J, Gorin AA, Raynor HA, Laska MN, Jeffery RW, Levy RL, Wing RR. Are standard behavioral weight loss programs effective for young adults? *International journal of obesity (2005)*. 2009;33(12):1374–1380.
38. Kula AJ, Prince DK, Katz R, Bansal N. Mortality Burden and Life-Years Lost Across the Age Spectrum for Adults Living with CKD. *Kidney360*. 2023;4(5):615–621.
39. Crouse JR, Raichlen JS, Riley WA, Evans GW, Palmer MK, O’Leary DH, Grobbee DE, Bots ML. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk

individuals with subclinical atherosclerosis: the METEOR Trial. *JAMA*. 2007;297(12):1344–1353.

40. Matthews KA, Crawford SL, Chae CU, Everson-Rose SA, Sowers MF, Sternfeld B, Sutton-Tyrrell K. Are changes in cardiovascular disease risk factors in midlife women due to chronological aging or to the menopausal transition? *Journal of the American College of Cardiology*. 2009;54(25):2366–2373.

41. Thurston RC, Karvonen-Gutierrez CA, Derby CA, El Khoudary SR, Kravitz HM, Manson JAE. Menopause versus chronologic aging: their roles in women's health. *Menopause (New York, N.Y.)*. 2018;25(8):849–854.

42. Lejsková M, Aluší Š, Valenta Z, Adámková S, Piňha J. Natural postmenopause is associated with an increase in combined cardiovascular risk factors. *Physiological research*. 2012;61(6):587–596.

43. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. *Archives of internal medicine*. 2008;168(14):1568–1575.

44. Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *European heart journal*. 2017;38(32):2478–2486.

45. Trimarco V, Izzo R, Morisco C, Mone P, Virginia Manzi M, Falco A, Pacella D, Gallo P, Lembo M, Santulli G, Trimarco B. High HDL (High-Density Lipoprotein) Cholesterol Increases Cardiovascular Risk in Hypertensive Patients. *Hypertension (Dallas, Tex. : 1979)*. 2022;79(10):2355–2363.

46. Liu C, Dhindsa D, Almuwaqqat Z, Ko YA, Mehta A, Alkhoder AA, Alras Z, Desai SR, Patel KJ, Hooda A, Wehbe M, Sperling LS, Sun Y V., Quyyumi AA. Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. *JAMA cardiology*. 2022;7(7):672–680.

47. Moradi H, Streja E, Kashyap ML, Vaziri ND, Fonarow GC, Kalantar-Zadeh K. Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2014;29(8):1554–1562.



## Tables

	Overall	CKM Stage 0	CKM Stage 1	CKM Stage 2
<b>Unweighted Nr.</b>	32848	3487	5703	17757
<b>Weighted Population</b>	215480397	17128893	39464629	121882777
<b>Variable</b>	<b>Weighted Prevalence % (95% CI)</b>			
<b>Overall</b>	100	7.9 (7.4-8.5)	18.3 (17.6-19.1)	56.6 (55.6-57.5)
<b>Female</b>	51.3 (50.6-51.9)	64.0 (61.1-66.9)	48.8 (46.7-50.8)	49.3 (48.3-50.2)
<b>Male</b>	48.7 (48.1-49.4)	36.0 (33.1-38.9)	51.2 (49.2-53.3)	50.7 (49.8-51.7)
<b>Age 18-24</b>	9.2 (8.6-9.8)	23.0 (20.6-25.5)	13.2 (11.8-14.5)	5.7 (5.1-6.4)
<b>Age 25-44</b>	37.1 (36.1-38.2)	57.8 (54.3-61.3)	50.2 (47.9-52.5)	32.8 (31.5-34.0)
<b>Age 45-64</b>	35.6 (34.6-36.5)	17.0 (14.4-19.6)	30.6 (28.4-32.7)	41.1 (39.9-42.3)
<b>Age &gt;=65</b>	18.1 (17.4-18.9)	2.2 (1.3-3.0)	6.1 (5.1-7.1)	20.4 (19.5-21.2)
<b>Hispanic*</b>	13.8 (12.4-15.3)	11.4 (9.4-13.3)	17.5 (15.3-19.7)	13.7 (12.1-15.2)
<b>Non-Hispanic White</b>	67.9 (65.9-69.9)	72.7 (69.6-75.8)	62.4 (59.5-65.3)	67.9 (65.6-70.1)
<b>Non-Hispanic Black</b>	11.1 (10.0-12.3)	8.3 (6.8-9.9)	12.8 (11.3-14.4)	11.3 (10.0-12.6)
<b>Non-Hispanic Asian**</b>	2.6 (2.2-3.0)	2.9 (2.2-3.6)	3.6 (2.9-4.4)	2.5 (2.1-2.9)
<b>Non-Hispanic Others</b>	4.5 (4.0-5.0)	4.7 (3.2-6.1)	3.7 (2.8-4.5)	4.7 (4.0-5.3)

**Table 1. Weighted Population Characteristics Overall and by CKM Syndrome Stages in US Adults**

Abbreviation: CKM, cardiovascular-kidney-metabolic syndrome.

\* Hispanic represents Mexican American and other Hispanic individuals.

\*\* non-Hispanic Asian participants were classified and oversampled since 2011.


Characteristic	Weighted Prevalence, % (95% CI)										P value
	1999-2000 n= 186356015	2001-2002 n= 195531851	2003-2004 n=201768320	2005-2006 n= 204518688	2007-2008 n= 212681297	2009-2010 n= 216303553	2011-2012 n= 221814830	2013-2014 n= 227000000	2015-2016 n= 231226225	2017-2020 n= 237963984	
CKM Stage 0	7.9 (6.0 - 9.7)	9.9 (7.8 - 11.9)	10.1 (8.2 - 11.9)	9.1 (6.9 - 11.3)	8.2 (6.8 - 9.7)	8.7 (6.7 - 10.60)	8.5 (6.5 - 10.4)	7.6 (5.9 - 9.4)	6.6 (4.3 - 9.0)	6.8 (5.3 - 8.3)	0.0018
CKM Stage 1	15.0 (12.8 - 17.3)	18.6 (15.6 - 21.7)	20.5 (17.5 - 23.5)	27.3 (25.1 - 29.6)	27.1 (24.8 - 29.4)	26.5 (23.3 - 29.7)	18.9 (16.5 - 21.4)	20.6 (18.7 - 22.6)	23.4 (20.4 - 26.5)	20.6 (18.7 - 22.4)	0.5
CKM Stage 2	57.3 (55.4-59.2)	55.4 (53.1 - 57.5)	53.8 (50.8 - 56.8)	47.5 (44.8 - 50.3)	48.8 (46.5 - 51.2)	49.0 (46.1 - 51.9)	56.6 (54.8 - 58.40)	54.8 (51.4 - 58.3)	53.7 (50.2 - 57.2)	54.6 (51.2 - 58.1)	0.87
<b>CKM Stage 0</b>											
Female	5.2 (3.8 - 6.5)	6.3 (4.8 - 7.8)	6.3 (4.6 - 8.1)	6.0 (4.1 - 7.9)	5.2 (4.0 - 6.5)	6.2 (5.0 - 7.3)	5.6 (4.3 - 7.1)	4.9 (3.6 - 6.2)	4.0 (2.1 - 6.0)	4.2 (3.0 - 5.4)	0.0039
Male	2.7 (1.6 - 3.8)	3.5 (2.4 - 4.7)	3.7 (2.4 - 5.0)	3.1 (2.0 - 4.3)	3.0 (2.2 - 3.8)	2.5 (1.5 - 3.5)	2.8 (2.0 - 3.7)	2.8 (1.8 - 3.7)	2.6 (1.5 - 3.7)	2.6 (1.9 - 3.3)	0.031
Age 18 - 24	1.2 (0.6 - 1.8)	2.3 (1.6 - 3.0)	2.3 (1.4 - 3.1)	1.9 (1.2 - 2.6)	2.2 (1.3 - 3.1)	1.5 (1.0 - 2.0)	2.3 (1.4 - 3.2)	1.7 (1.1 - 2.4)	1.5 (0.8 - 2.2)	1.9 (1.3 - 2.6)	0.88
Age 25 - 44	5.3 (3.7 - 6.9)	5.9 (4.3 - 7.4)	6.2 (4.7 - 7.6)	4.8 (3.0 - 6.5)	4.8 (3.9 - 5.8)	5.7 (3.8 - 7.5)	4.5 (3.3 - 5.8)	4.2 (2.6 - 5.7)	3.4 (2.2 - 4.6)	3.6 (2.6 - 4.5)	< 0.001
Age 45 - 64	1.2 (0.7 - 1.8)	1.6 (0.7 - 2.4)	1.4 (0.6 - 2.3)	2.2 (1.4 - 2.9)	1.1 (0.6 - 1.6)	1.1 (0.7 - 1.6)	1.4 (0.6 - 2.1)	1.6 (0.8 - 2.3)	1.6 (0.1 - 3.0)	1.1 (0.7 - 1.6)	0.58
*Age >= 65	0.1 (0.0 - 0.3)	0.1 (0.0 - 0.2)	0.2 (0.0 - 0.5)	0.2 (0.0 - 0.4)	0.1 (0.0 - 0.3)	0.3 (0.0 - 0.6)	0.2 (0.0 - 0.4)	0.2 (0.0 - 0.5)	0.1 (0.0 - 0.4)	0.2 (0.0 - 0.4)	0.53
<b>CKM Stage 1</b>											
Female	6.2 (4.2 - 8.3)	7.9 (6.4 - 9.3)	9.5 (8.3 - 10.7)	11.9 (9.7 - 14.1)	13.4 (11.4 - 15.4)	12.56 (9.9 - 15.2)	9.8 (7.7 - 11.9)	10.1 (8.9 - 11.4)	13.0 (11.3 - 14.6)	9.2 (7.8 - 10.7)	0.18
Male	8.8 (7.3 - 10.2)	10.8 (8.4 - 13.2)	11.0 (8.7 - 13.3)	15.5 (13.3 - 17.6)	13.7 (11.9 - 15.4)	13.9 (12.4 - 15.4)	9.1 (8.1 - 10.2)	10.5 (9.2 - 11.8)	10.4 (8.6 - 12.3)	11.3 (9.3 - 13.3)	0.95
Age 18 - 24	0.9 (0.5 - 1.4)	2.1 (1.3 - 2.9)	2.0 (1.3 - 2.6)	3.5 (2.8 - 4.3)	2.9 (2.3 - 3.5)	3.3 (2.2 - 4.2)	2.1 (1.5 - 2.7)	2.5 (1.6 - 3.3)	3.6 (2.5 - 4.6)	2.7 (1.9 - 3.4)	0.079
Age 25 - 44	8.7 (6.6 - 10.9)	10.0 (7.8 - 12.2)	9.8 (7.5 - 12.1)	11.8 (10.2 - 13.5)	11.2 (9.4 - 13.1)	12.4 (10.9 - 14.0)	9.6 (7.8 - 11.5)	11.2 (9.8 - 12.5)	11.7 (9.8 - 13.6)	9.8 (8.1 - 11.5)	0.36
Age 45 - 64	4.1 (3.0 - 5.3)	5.6 (3.6 - 7.6)	7.3 (5.2 - 9.4)	9.5 (7.6 - 11.5)	11.2 (8.9 - 13.4)	8.9 (7.2 - 10.6)	6.2 (3.8 - 8.6)	6.1 (4.9 - 7.3)	6.0 (4.9 - 7.2)	6.6 (5.4 - 7.9)	0.89
Age >= 65	1.2 (0.5 - 2.0)	1.0 (0.6 - 1.3)	1.4 (0.6 - 2.1)	2.4 (1.7 - 3.2)	1.8 (1.2 - 2.4)	1.9 (1.4 - 2.4)	1.0 (0.5 - 1.5)	0.9 (0.5 - 1.2)	2.1 (1.0 - 3.2)	1.5 (0.8 - 2.1)	0.75
<b>CKM Stage 2</b>											
Female	28.1 (25.7 - 30.4)	27.3 (25.1 - 29.5)	26.0 (23.5 - 28.5)	24.3 (22.1 - 26.6)	23.6 (21.7 - 25.5)	24.1 (22.1 - 26.1)	27.4 (25.2 - 29.6)	28.2 (25.7 - 30.7)	25.9 (23.7 - 28.1)	28.3 (26.7 - 30.0)	0.77
Male	29.2 (27.5 - 31.0)	28.1 (25.7 - 30.5)	27.9 (25.5 - 30.3)	23.2 (21.6 - 24.8)	25.2 (22.8 - 27.7)	24.9 (22.4 - 27.3)	29.2 (26.9 - 31.6)	26.7 (24.5 - 28.8)	27.8 (25.8 - 29.9)	26.3 (23.9 - 28.7)	0.57
Age 18 - 24	3.7 (1.9 - 5.5)	3.2 (2.2 - 4.3)	4.0 (2.7 - 5.4)	2.5 (1.5 - 3.4)	2.8 (1.4 - 4.2)	2.9 (2.0 - 3.8)	3.4 (2.0 - 4.9)	3.6 (2.7 - 4.6)	2.6 (1.7 - 3.4)	2.9 (2.1 - 3.7)	0.2
Age 25 - 44	23.2 (21.4 - 25.0)	19.2 (17.5 - 21.0)	18.8 (16.4 - 21.2)	15.7 (13.5 - 18.0)	16.3 (14.3 - 18.2)	14.3 (12.2 - 16.4)	18.2 (15.7 - 20.7)	16.8 (15.2 - 18.3)	15.4 (13.1 - 17.8)	16.8 (14.5 - 19.2)	0.018
Age 45 - 64	20.1 (17.9 - 22.2)	23.2 (20.9 - 25.5)	21.4 (18.5 - 24.4)	19.7 (17.8 - 21.7)	20.3 (17.7 - 22.9)	20.3 (18.2 - 22.4)	24.6 (22.0 - 27.2)	22.4 (20.0 - 24.9)	23.0 (20.7 - 25.4)	21.7 (19.6 - 23.8)	0.33
Age >= 65	10.3 (8.4-12.2)	9.7 (8.5 - 10.9)	9.6 (8.2 - 11.0)	9.6 (7.3 - 11.8)	9.5 (7.9 - 11.0)	11.5 (10.2 - 12.7)	10.3 (9.1 - 11.6)	12.0(10.3-13.7)	12.7 (11.0 - 14.3)	13.2 (11.4 - 15.0)	< 0.001

**Table 2. Trends in weighted Overall and Sex-/Age-stratified Prevalence of CKM stages in US Adults, 1999-2020**

Abbreviations: CKM, cardiovascular-kidney-metabolic syndrome.

\*Estimate may be unreliable with relative standard error >30%


## Figures



**Figure 1. Sex-, Age- and race/ethnicity-stratified Prevalence in CKM Syndrome Stage 0-2**

Sex-stratified prevalence of CKM syndrome stage 0-2 in US female adults or male adults (A), proportion of CKM syndrome stage 0-2 in different age groups (B), prevalence of CKM stage 0-2 in US adults stratified by combination of sex and age (C), proportion of CKM syndrome stage 0-2 in different race/ethnicity groups (D). All prevalence estimates are presented as weighted prevalence.


Abbreviations: CKM, cardiovascular-kidney-metabolic syndrome.



**Figure 2. Overall Prevalence of CKD, Diabetes, Hypertension, Hypertriglyceridemia and MetS in US Adults with CKM syndrome Stage 2**

Prevalence estimates are presented as weighted prevalence of noninstitutionalized US adults at stage 2.

Abbreviations: CKM, cardiovascular-kidney-metabolic syndrome; CKD, chronic kidney disease; MetS, metabolic syndrome.




**Figure 3. Trends in Prevalence of CKM Stage 0-2 among US adult Population, 1999-2000**


CKM stage 0  $P$  for trends = 0.0018; CKM stage 1  $P$  for trends = 0.5; CKM stage 2  $P$  for trends = 0.87. All prevalence estimates are presented as weighted prevalence of noninstitutionalized US adults. Error bars indicate 95% CIs

CKM, cardiovascular kidney-metabolic syndrome.


**A**



**B**



**C**



**Figure 4. Trends in Sex-stratified Prevalence of CKM Stage 0-2, 1999-2020**


CKM stage 0: female  $P$  for trends = 0.0039, male  $P$  for trends = 0.031; CKM stage 1: female  $P$

for trends = 0.18, male  $P$  for trends = 0.95; CKM stage 2: female  $P$  for trends = 0.77, male  $P$  for trends = 0.57. All prevalence estimates are presented as weighted prevalence of noninstitutionalized US adults. Error bars indicate 95% CIs.


CKM, cardiovascular kidney-metabolic syndrome.




**A**



**B**



**C**




**Figure 5. Trends in Age-stratified Prevalence of CKM Stage 0-2, 1999-2020**

CKM stage 0: age 18-24  $P$  for trends = 0.88, age 24-44  $P$  for trends < 0.001, age 45-64  $P$  for

trends = 0.58, age $\geq$ 65 *P* for trends = 0.53; CKM stage 1: age 18-24 *P* for trends = 0.079, age 24-44 *P* for trends = 0.36, age 45-64 *P* for trends = 0.89, age $\geq$ 65 *P* for trends = 0.75; CKM stage 2: age 18-24 *P* for trends = 0.2, age 24-44 *P* for trends = 0.018, age 45-64 *P* for trends = 0.33, age $\geq$ 65 *P* for trends < 0.001. All prevalence estimates are presented as weighted prevalence of noninstitutionalized US adults. Error bars indicate 95% CIs.

CKM, cardiovascular kidney-metabolic syndrome.







**Figure 6. Prevalence of CKM Syndrome Stage 0-1 and undefined stage (CKM SX) in US Adults**


Prevalence estimates are shown as weighted prevalence of noninstitutionalized US adults.


CKMSX represents US adults, who did not yet fulfill the criterion for CKM stage 1 but had abnormalities excluding them from stage 0.




Abbreviations: CKM, cardiovascular-kidney-metabolic syndrome; S0, stage 0; SX, undefined stage; S1, stage 1; S2, stage 2.





















factor(Stage, levels = stage\_order)

